Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
New England Journal of Medicine · 15.08.2024 · 391 (7) · 585-597
DOI: 10.1056/nejmoa2402614 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 15.08.2024. Verfasst von Shun Lu und 24 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai (S.L.), the Cancer Cent…. Hauptthemen laut MEDLINE: Acrylamides, Aniline Compounds, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 357-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai (S.L.), the Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Sci…
Förderung
- AstraZeneca
Zitieren
APA
Lu, S., Kato, T., Dong, X., Ahn, M. J., Quang, L. V., Soparattanapaisarn, N., Inoue, T., Wang, C. L., Huang, M., Yang, J. C., Cobo, M., Özgüroğlu, M., Casarini, I., Khiem, D. V., Sriuranpong, V., Cronemberger, E., Takahashi, T., Runglodvatana, Y., Chen, M., …, & LAURA Trial Investigators (2024). Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC. New England Journal of Medicine, 391(7), 585-597. https://doi.org/10.1056/nejmoa2402614
Vancouver
Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, et al. Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC. New England Journal of Medicine. 2024;391(7):585-597. doi:10.1056/nejmoa2402614
BibTeX
@article{Lu2024,
author = {Lu, Shun and Kato, Terufumi and Dong, Xiaorong and Ahn, Myung-Ju and Quang, Le-Van and Soparattanapaisarn, Nopadol and Inoue, Takako and Wang, Chih-Liang and Huang, Meijuan and Yang, James Chih-Hsin and Cobo, Manuel and Özgüroğlu, Mustafa and Casarini, Ignacio and Khiem, Dang-Van and Sriuranpong, Virote and Cronemberger, Eduardo and Takahashi, Toshiaki and Runglodvatana, Yotsawaj and Chen, Ming and Huang, Xiangning and Grainger, Ellie and Ghiorghiu, Dana and van der Gronde, Toon and Ramalingam, Suresh S and LAURA Trial Investigators, LAURA Trial Investigators},
title = {Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC},
journal = {New England Journal of Medicine},
year = {2024},
volume = {391},
number = {7},
pages = {585--597},
doi = {10.1056/nejmoa2402614}
}
EUVIMED